PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus
Yin Tong(Queen Mary Hospital), Wenbin Qian(Ministry of Education of the People's Republic of China)
Cited by 40
Related Papers
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234
Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
|Journal of Experimental & Clinical Cancer Research|2018|86
Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells
|International Journal of Oncology|2016|42